SWOG S1803 (Multiple Myeloma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiple myeloma patients live longer.
What is the Condition Being Studied?
Multiple myeloma patients who have received a stem cell transplant
Who Can Participate in the Study?
Adults with multiple myeloma who have had a stem cell transplant.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (like flipping a coin) to 1 of 2 groups:
Study Details
Full Title
SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator
Cellular Therapy Specialist
Protocol Number
IRB:
PRO00104040
NCT:
NCT04071457
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-681-4769